Skip to main content
Article thumbnail
Location of Repository

Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis

By M E M Oude Luttikhuis, J E Powell, S A Rees, T Genus, S Chughtai, P Ramani, J R Mann and C M McConville


Neuroblastoma is a heterogeneous tumour and its effective clinical management is dependent on accurate prognostic evaluation. In approximately 25% of patients amplification of the MYCN oncogene is known to be associated with a poor outcome. In order to identify additional molecular markers with prognostic potential in non-MYCN-amplified neuroblastomas, we looked for a correlation between clinical outcome and loss of heterozygosity (LOH) on four chromosomes that frequently show alteration in neuroblastoma (chromosomes 3, 4, 11 and 14). Chromosome 11q loss (with frequent parallel loss of chromosomes 3p, 4p and/or 14q) was found exclusively in tumours without MYCN amplification and was significantly associated with poor event-free survival. The 2-year event-free survival rate for 11q LOH cases was 30%, compared to 34% for MYCN-amplified cases and 100% for cases without these abnormalities. While 11q LOH was associated predominantly with advanced-stage disease, 2 cases with low-stage disease and 11q LOH both suffered relapses. We conclude that chromosome 11q loss defines a biologically distinct group of tumours without MYCN amplification that appear to have potential for aggressive metastatic growth. Thus this genetic alteration may be an important new prognostic marker in neuroblastoma. © 2001 Cancer Research Campaign

Topics: Regular Article
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1997). Biology and genetics of human neuroblastomas.
  2. (1996). Connatal localized neuroblastoma.
  3. (1998). De Paepe A and Speleman F
  4. (1992). Deletion mapping of chromosome-14q and chromosome-1p in human neuroblastoma.
  5. (1999). Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
  6. (2001). Loss of heterozygosity (LOH) from chromosome 14q in neuroblastoma.
  7. (1997). Molecular biology of colorectal cancer.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.